JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
NKCC1A-expressing Xenopus oocytes
Reaction Conditions
0.03 ~ 100 μM bumetanide for 5 min incubation
Applications
Bumetanide inhibited the 86Rb+ uptake in NKCC1A-expressing oocytes in a dose-dependent manner. At the doses ranging from 30 to 100 μM, bumetanide reduced the 86Rb+ uptake to background levels.
Animal models
Dogs
Dosage form
0.1 mg/kg
Injected intravenously
Bumetanide (0.1 mg/kg) significantly increased urine flow and sodium and potassium excretion, as well as decreased sodium reabsorption, in anesthetized dogs. In addition, bumetanide was approximately 30-fold more potent than furosemide in enhancing sodium excretion.
Note
The technical data provided above is for reference only.
References:
1. Lykke K, Töllner K, Feit PW, et al. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A. Epilepsy & Behavior, 2016, 59: 42-49.
2. Cohen MR, Hinsch E, Vergona R, et al. A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog. Journal of Pharmacology and Experimental Therapeutics, 1976, 197(3): 697-702.